Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Arthurs, Benjamin, Wunderle, Kathy, Hsu, Maylee, Kim, Suil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369366/
https://www.ncbi.nlm.nih.gov/pubmed/28377877
http://dx.doi.org/10.1016/j.rmcr.2017.03.011
_version_ 1782518109250256896
author Arthurs, Benjamin
Wunderle, Kathy
Hsu, Maylee
Kim, Suil
author_facet Arthurs, Benjamin
Wunderle, Kathy
Hsu, Maylee
Kim, Suil
author_sort Arthurs, Benjamin
collection PubMed
description We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clinicians should be aware of potential Aspergillus infections in patients treated with this drug.
format Online
Article
Text
id pubmed-5369366
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53693662017-04-04 Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia Arthurs, Benjamin Wunderle, Kathy Hsu, Maylee Kim, Suil Respir Med Case Rep Case Report We report a case of invasive pulmonary aspergillosis in a patient taking ibrutinib, a Bruton's tyrosine kinase inhibitor used to treat refractory chronic lymphocytic leukemia. We hypothesize that ibrutinib promoted this infection by suppressing innate immune responses against Aspergillus. Clinicians should be aware of potential Aspergillus infections in patients treated with this drug. Elsevier 2017-03-20 /pmc/articles/PMC5369366/ /pubmed/28377877 http://dx.doi.org/10.1016/j.rmcr.2017.03.011 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Arthurs, Benjamin
Wunderle, Kathy
Hsu, Maylee
Kim, Suil
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
title Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
title_full Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
title_fullStr Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
title_full_unstemmed Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
title_short Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
title_sort invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369366/
https://www.ncbi.nlm.nih.gov/pubmed/28377877
http://dx.doi.org/10.1016/j.rmcr.2017.03.011
work_keys_str_mv AT arthursbenjamin invasiveaspergillosisrelatedtoibrutinibtherapyforchroniclymphocyticleukemia
AT wunderlekathy invasiveaspergillosisrelatedtoibrutinibtherapyforchroniclymphocyticleukemia
AT hsumaylee invasiveaspergillosisrelatedtoibrutinibtherapyforchroniclymphocyticleukemia
AT kimsuil invasiveaspergillosisrelatedtoibrutinibtherapyforchroniclymphocyticleukemia

Ejemplares similares